The United States of America As Represented by the Department of Health

Blanchette Rockefeller Neurosciences Institute

Cognitive Research Enterprises, Inc.

Rene Etcheberrigaray

Daniel L Alkon

Christopher S Kim

Yi-Fan Han

Tom J Nelson

Gary E Gibson

Etsuro Ito

The present invention relates to compositions and methods to modulate &#x3b1;-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).

Methods for Alzheimer's disease treatment and cognitive enhancement

Methods for Alzheimer'S disease treatment and cognitive enhancement

The present invention relates to compositions and methods to modulate &agr;-secretase and/or to improve cognitive ability. The invention further relates the improved/enhanced cognitive ability in diseased individuals, particularly Alzheimer's Disease patients, and treatment thereof through increased sAPP production. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are compounds preferred for use with the present composition. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP comprising the activation of protein kinase C (PKC) by administering an effective amount of PKC activator(s).

Methods for Alzheimer's Disease treatment and cognitive enhancement

The present invention provides methods for the diagnosis of Alzheimer's disease using human cells. Specifically, one method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels. Other methods detect differences between the memory associated GTP binding Cp20 protein levels between Alzheimer's and normal cells.

Cell tests for Alzheimer's disease

Cell tests for alzheimer's disease

The present invention is a method for the diagnosis of Alzheimer's disease using human cells. Specifically, the method detects differences between potassium channels in cells from Alzheimer's patient and normal donors, and differences in intracellular calcium concentrations between Alzheimer's and normal cells in response to chemicals known to increase intracellular calcium levels.

Diagnostic tests for alzheimers disease

Growing community of inventors

Bethesda, MD, United States of America

Rene Etcheberrigaray